NDAORALTABLET, EXTENDED RELEASE
Approved
Sep 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
JENLOGA (clonidine hydrochloride) by Teva is clinical pharmacology clonidine stimulates alpha-adrenoreceptors in the brain stem. First approved in 2009.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JENLOGA is an extended-release oral tablet formulation of clonidine hydrochloride, an alpha-2-adrenergic agonist that reduces sympathetic outflow from the central nervous system. It is indicated for ocular redness and works by stimulating alpha-adrenoreceptors in the brain stem to decrease peripheral resistance, heart rate, and blood pressure. Peak plasma levels occur within 1-3 hours, with antihypertensive effects reaching maximum within 2-4 hours.
LOE Approaching
As LOE approaches, commercial team focus will shift from growth to transition management, with potential consolidation of sales roles and emphasis on retention strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY Clonidine stimulates alpha-adrenoreceptors in the brain stem. This action results in reduced sympathetic outflow from the central nervous system and in decreases in peripheral resistance, renal vascular resistance, heart rate, and blood pressure. Clonidine hydrochloride…
Worked on JENLOGA at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.